Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Rhea-AI Summary
Cardiol Therapeutics (NASDAQ: CRDL) announced a live interview with Barchart on X today, April 14, 2026, at 12:00 PM EDT featuring CEO David Elsley. Topics include the pivotal Phase III MAVERIC trial for recurrent pericarditis, published Phase II ARCHER myocarditis results, and next-gen drug CRD-38.
Investors can join live at x.com/Barchart; a full recording will be posted on Cardiol's X channel (@CardiolRx) and Barchart's channel after the event.
Positive
- None.
Negative
- None.
News Market Reaction – CRDL
In the Apr 14 session, CRDL gained 2.94%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | ARCHER results published | Positive | +1.9% | Publication of Phase II ARCHER myocarditis data with significant LV mass reduction. |
| Jan 13 | MAVERIC enrollment update | Positive | +1.3% | Surpassing 50% enrollment in pivotal Phase III MAVERIC pericarditis trial. |
| Dec 01 | New ARCHER data | Positive | -9.5% | New Phase II ARCHER data showing structural heart improvements after 12 weeks. |
| Nov 05 | ARCHER data presentation | Positive | +3.8% | Announcement of upcoming full ARCHER data presentation at ESC meeting. |
| Aug 06 | ARCHER topline results | Positive | -20.7% | Topline Phase II ARCHER results with ECM and LV mass improvements in myocarditis. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial updates have produced mixed reactions, with 3 positive and 2 negative moves, and an average move of -4.65%, indicating that favorable data has not always translated into sustained price strength.
Over recent months, Cardiol has steadily advanced CardiolRx across inflammatory heart conditions. Topline and detailed Phase II ARCHER data in acute myocarditis, including significant reductions in left ventricular mass and structural improvements, were followed by conference presentations and publication. In parallel, the pivotal Phase III MAVERIC trial in recurrent pericarditis surpassed 50% enrollment with plans for ~110 patients. Today’s interview highlighting MAVERIC, ARCHER, and next‑generation candidate CRD‑38 fits this ongoing clinical execution narrative.
Key Terms
phase iii medical
phase ii medical
recurrent pericarditis medical
acute myocarditis medical
heart failure medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.
Interview Topics:
- The ongoing pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis
- Results from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditis
- The Company's next generation drug, CRD-38, in development for heart failure
Interview details:
Date: April 14, 2026
Time: 12:00 PM EDT
Platform: X
Host Account on X: @Barchart
Join Live Interview at: x.com/Barchart
After the event, a full recording of the interview will be available on the Company's X channel (@CardiolRx) and Barchart's (@Barchart).
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.
The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.
The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.
For further information, please contact:
Investor.relations@cardiolrx.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292336